
Long-Acting Injectable HIV Therapy: Improving Viral Suppression in African Adults with Adherence Challenges
A Phase 3b trial in eastern and southern Africa showed that long-acting injectable cabotegravir plus rilpivirine is noninferior to oral dolutegravir-based therapy for maintaining viral suppression in HIV patients facing adherence challenges





